Top

Published in:

01-09-2014 | Review

Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review

Authors: S. J. Ioannides, P. L. Barlow, J. M. Elwood, D. Porter

Published in: Breast Cancer Research and Treatment | Issue 2/2014

Abstract

Aromatase inhibitors (AIs) decrease the production of oestrogen, decreasing stimulation of hormone receptor-positive breast cancer. Theoretically, AIs may be less effective in obese women, due to the greater quantity of aromatase in peripheral fatty tissue. We performed a systematic review to assess the effect of obesity on AI efficacy in breast cancer treatment. The review followed PRISMA guidelines. Studies included were interventional or observational studies with comparison groups, of postmenopausal women with hormone receptor-positive breast cancer on treatment with an AI, alone or in combination with other drugs, in which body mass index or another measure of obesity was recorded. Studies in all languages were included; if published as an abstract only, authors were contacted for further information. Outcome measures included overall survival, disease-free survival or time to progressive disease, survival from the start of therapy, mortality measures, local or distant recurrence of primary cancer and time to recurrence. Of 2,344 citations identified from five databases, eight studies met the criteria for inclusion; three randomised controlled trials and five retrospective cohort studies. Due to variability in study factors, it was not possible to perform a quantitative meta-analysis. However, the systematic review showed a trend towards a negative effect of obesity on AI efficacy. There is evidence of a negative effect of obesity on AI efficacy in postmenopausal hormone receptor-positive breast cancer, but the size of the effect cannot be assessed. More information is needed before clinical recommendations are made.

Bagchi D, Preuss H (2013) Obesity: epidemiology, pathophysiology, and prevention, vol 2nd. CRC Press, New York

Niraula S, Ocana A, Ennis M et al (2012) Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 134:769–781PubMedCrossRef

National Health Institute. Obesity and cancer risk. secondary obesity and cancer risk. http://www.cancer.gov/cancertopics/factsheet/Risk/obesity. Accessed 18 July 2014

GLOBOCAN (2012) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Secondary GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 18 July 2014

Sanford M, Plosker GL (2008) Anastrozole. Drugs 68(9):1319–1340. doi:10.2165/00003495-200868090-00007 CrossRef

Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431–2442PubMedCrossRef

Morris PG, Hudis CA, Giri D et al (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 4(7):1021–1029CrossRef

Subbaramaiah K, Howe LR, Bhardwaj P et al (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 4(3):329–346CrossRef

Goodwin PJ, Pritchard KI (2010) Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin Oncol 28(21):3405–3407PubMedCrossRef

10.

Wolters R, Schwentner L, Regierer A et al (2012) Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Treat 131(3):925–931PubMedCrossRef

11.

Moher D, Liberati A, Tetzlaff J, et al, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed.1000097

12.

Ewertz M, Gray KP, Regan MM et al (2012) Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 30(32):3967–3975PubMedCentralPubMedCrossRef

13.

Gnant M, Pfeiler G, Stoger H et al (2013) The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer 109(3):589–596PubMedCentralPubMedCrossRef

14.

Sendur MAN, Aksoy S, Zengin N et al (2012) Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. Br J Cancer 107(11):1815–1819PubMedCentralPubMedCrossRef

15.

Sestak I, Distler W, Forbes JF et al (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411–3415PubMedCrossRef

16.

Sahin U, Petekkaya I, Arslan C et al (2012) Impact of obesity in postmenopausal early breast cancer patients receiving frontline adjuvant aromatase inhibitors. J Clin Oncol 30(suppl):e11020

17.

Michaud LB, Buzdar AU, Rubin S et al (2002) The efficacy of anastrozole is not dependent upon body mass index (BMI) in postmenopausal women with advanced breast cancer (BC). Proc Am Soc Clin Oncol 21:55a

18.

Schmid P, Possinger K, Bohm R et al (2000) Body mass index as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or Megestrol Acetate. Proc Am Soc Clin Oncol 19:103a

19.

Michaud LB, Buzdar AU (1999) Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf 27(4):297–309CrossRef

20.

Cuzick J, Sestak I, Baum M et al (2011) 10-year analysis of the ATAC trial: wrong conclusion?—Authors’ reply. lancet 12:201–312CrossRef

21.

Jakesz R, Greil R, Gnant M (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast and colorectal cancer study group trial 6a. J Natl Cancer Inst 99:11845–11853CrossRef

22.

Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 12(12):1101–1108. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/418/CN-00804418/frame.html. Accessed 18 July 2014

23.

Goss PE (2006) Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Semin Oncol 33(2 Suppl 7):S8–12 doi:10.1053/j.seminoncol.2006.03.025

24.

Mamounas EP, Jeong JH, Wickerham DL et al (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 26(12):1965–1971. doi:10.1200/jco.2007.14.0228 PubMedCrossRef

25.

Pfeiler G, Konigsberg R, Fesl C et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29(19):2653–2659PubMedCrossRef

26.

Folkerd E, Dixon J, Renshaw L et al (2012) Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 30(24):2977–2980PubMedCrossRef

27.

Kittaneh M, Gluck S (2011) Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer 5:209–226. doi:10.4137/BCBCR.S6234 PubMedCentralPubMed

28.

Geisler J, Haynes B, Anker G et al (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20(3):751–757PubMedCrossRef

29.

Gershanovich M, Chaudri HA, Campos D et al (1998) Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9:639–645PubMedCrossRef

30.

Gnant M, Mlineritsch B, Stoeger H et al (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7):631–641PubMedCrossRef

31.

Bhatnagar AS, Brodie AMH, Long BJ et al (2001) Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem and Mol Biol 76(1–5):199–202. doi:10.1016/S0960-0760(01)00050-4 CrossRef

32.

Miller W (2008) Background and development of aromatase inhibitors. In: BJA F (ed) Milestones in drug therapy, aromatase inhibitiors, 2nd edn. pp 1–21

33.

Dowsett M, Coombes RC (1994) Second generation aromatase inhibitor—4-hydroxyandrostenedione. Breast Cancer Res Treat 30(1):81–87. doi:10.1007/BF00682742 PubMedCrossRef

34.

Dixon JM, Renshaw L, Young O et al (2008) Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26(10):1671–1676. doi:10.1200/JCO.2007.13.9279 PubMedCrossRef

35.

Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39(16):2318–2327PubMedCrossRef

36.

World Health Organization. BMI classification. Secondary BMI classification. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed 18 July 2014

37.

Jonat W, Howell A, Blomqvist C et al (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A(3):404–412PubMedCrossRef

38.

Buzdar AU, Jones SE, Vogel CL et al (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. The Arimidex Study Group. Cancer 79:730–739. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/225/CN-00204225/frame.html. Accessed 18 July 2014

39.

Ortega AF, Lopez LJ, Villaro GV et al (2011) Individualization of treatment strategies. Adv Ther 28(Suppl 6):19–38CrossRef

Title: Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review
Authors: S. J. Ioannides
P. L. Barlow
J. M. Elwood
D. Porter
Publication date: 01-09-2014
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-3091-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Unvalidated antibodies and misleading results

Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy

Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer

Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival

Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer